Takuma Nomiya MD PhD

Director of Tokyo MI Clinic. (Tokyo, Japan)

e-mail: nomiya-rad@umin.ac.jp

MEDICAL LICENSURE

Full Medical License (Japan)   #395214

BOARD CERTIFICATION

August 2003 Board Certified Member of the Japanese Radiological Society #4234

October 2006 Board Certified Member of the Japanese Society of Therapeutic Raditation Oncology #536

April 2008 Board Certified Member of the Japanese Board of Cancer Therapy #07101075

January 2009 Board Certified Member of the Japan Esophageal Society #0444

December 2011 Medical Instructor of the Japanese Society for Palliative Medicine #1098

February 2012 Medical Clnical Instructor, Ministry of Health Labour and Welfare, Japan.

PROFESSIONAL AND SOCIETY MEMBERSHIPS

Membership:

Japanese Society of Radiology

Japanese Society of Therapeutic Radiation Oncology

The Society for Integrative Medicine Japan:

Japan Holistic Medical Society

PRESENT/PREVIOUS POSITION OR ACADEMIC RANK

2012-2015 The Head of medical staff, National Institute of Radiological Sciences, Chiba, Japan

2012-2018 A delegate of the Japanese Society of Therapeutic Raditation Oncology

2012- Associate Professor, Yamagata University Hospital, Yamagata, Japan

2006- Visiting Researcher, National Insutitute of Radiological Sciences, Chiba, Japan

2004-2006  Medical Staff, Hiraka General Hospital, Yokote, Japan

POST GRADUATE TRAINING

1998-2000  Resident in Radiation Oncology, Tohoku University Hospital, Sendai, Japan

2000-2004  Fellow in Radiation Oncology, Tohoku University Hospital, Sendai, Japan

EDUCATION

1992-1998  M.D., Tohoku University School of Medicine, Sendai, Japan.

2000-2003  Ph.D., Tohoku University Graduate School of Medicine, Sendai, Japan.

• Clinical Oncology
• Chemo-Radiation Therapy
• Integrative Therapy
• Molecular Biology
• Radiation Biology/Physics
• Mathematical Model
• Meditation Medicine
• Metaphysics

• Nomiya T, Akamatsu H, Harada M, Ota I, Hagiwara Y, Ichikawa M, Miwa M, Kawashiro S, Hagiwara M, Chin M, Hashizume E, Nemoto K. Modified Simultaneous Integrated Boost Radiotherapy for an Unresectable Huge Refractory Pelvic Tumor. World J Gastroentero 2014 (in-press)
• Nomiya T, Akamatsu H, Harada M, Ota I, Hagiwara Y, Ichikawa M, Miwa M, Suzuki A, Nemoto K. Modified Simultaneous Integrated Boost Radiotherapy for Unresectable Locally Advanced Breast Cancer: Preliminary Results of a Prospective Clinical Trial. Clin Breast Cancer. 2014 Nov 15. pii: S1526-8209(14)00203-1. doi: 10.1016/j.clbc.2014.09.011. [Epub ahead of print]
• Nomiya T, Akamatsu H, Harada M, Ota I, Hagiwara Y, Ichikawa M, Miwa M, Mizutani M, Kato T, Nagaoka A, Tomita Y, Nemoto K. Modified Simultaneous Integrated Boost Radiotherapy for Large Retroperitoneal Malginant Tumor: A Case Report of Nobel Technique. Oncol Lett 2014 (in-press).
• Nomiya T, Tsuji H, Maruyama K, Toyama S, Suzuki H, Akakura K, Shimazaki J, Nemoto K, Kamada T, Tsujii H, Working group for Genitourinary Tumors. Phase I/II Trial of Definitive Carbon Ion Radiotherapy for Prostate Cancer: Evaluation of Shortening of Treatment Period to 3 weeks. Br J Cancer. 2014 May 13;110(10):2389-95.
• Nomiya T, Tsuji H, Maruyama K, Kamada T, Tsujii H. Up-to-date results of carbon-ion radiotherapy for prostate cancer. Journal of Radiation Research, 2014, 55, i28–i29
• Nomiya T, Kaneko T, Goto J, Harada M, Akamatsu H, Hagiwara Y, Ota I, Nemoto K. Relationship between Serum Reactive Oxidative Metabolite Level and Skin Reaction in an Irradiated Rat Model. Free Radic Res. 2014 May;48(5):572-9.
• Nomiya T, Tsuji H. Chapter 28: Renal cell carcinoma. Tsujii H et al. (eds.), Carbon Ion Radiotherapy: Principles Practices, and Treatment Planning. 2014, Springer Japan.
• Nomiya T. Discussions on Target Theory: Past and Present. J Radiat Res. 2013 Nov 1;54(6):1161-3.
• Nomiya T, Tsuji H, Toyama S, Maruyama K, Nemoto K, Tsujii H, Kamada T. Management of high-risk prostate cancer: Radiation therapy and hormonal therapy. Cancer Treat Rev. 39: 872-878,2013.
• Nomiya T, Harada M, Sudo H, Ota I, Ichikawa M, Suzuki M, Murakami M, Nemoto K. Radiotherapy for inoperable and refractory endometriosis presenting with massive hemorrhage: a case report. J Med Case Rep. 2012 Sep 18;6(1):308.
• Nomiya T, Teruyama K, Wada H, Nemoto K. Time course of pain relief in patients treated with radiotherapy for cancer pain: a prospective study. Clin J Pain. 2010 Jan;26(1):38-42.
• Nomiya T, Nemoto K, Wada H, Takai Y, Yamada S. Long-term results of radiotherapy for T1a and T1bN0M0 glottic carcinoma. Laryngoscope 2008 Aug;118(8):1417-1421.
• Nomiya T, Tsuji H, Hirasawa N, Kato H, Kamada T, Mizoe J, Kishi H, Kamura K, Wada H, Nemoto K, Tsujii H. Carbon Ion Radiation Therapy for Primary Renal Cell Carcinoma: Initial Clinical Experience. Int J Radiat Oncol Biol Phys. 2008 Nov 1;72(3):828-33.
• Nomiya T, Nemoto K, Kumabe T, Takai Y, Yamada S. Prospective single-arm study of 72 Gy hyperfractionated radiation therapy and combination chemotherapy for anaplastic astrocytomas. BMC Cancer. 2008 Jan 16;8(1):11
• Nomiya T, Teruyama K, Wada H, Nemoto K. Chemo-radiation therapy for patient with a giant esophageal fistula. World J Gastroenterol. 13(15): 2250-2254. 2007.
• Nomiya T, Nemoto K, Yamada S. Relationships between biological and clinicopathologic features in esophageal carcinoma. Oral Cancer Research Advances. Nova Publisher Inc.　p11-50.
• Nomiya T, Nemoto K, Kumabe T, Takai Y, Yamada S. Prognostic significance of surgery and radiation therapy in cases of anaplastic astrocytoma: retrospective analysis of 170 cases. J Neurosurgery 2007 Apr;106(4):575-81.
• Nomiya T, Teruyama K, Takahashi S, Saitou M, Yamada S. Unusual behavior of foreign body granuloma that grew rapidly in the radiation field during radiation therapy: Report of 2 cases. Radiation medicine. 24(7): 525-528, 2006
• Nomiya T, Nemoto K, Nakata E, Takai Y, Yamada S. Expression of thymidine phosphorylase and VEGF in esophageal squamous cell carcinoma. Oncol Rep. 2006 Jun;15(6):1497-501.
• Nomiya T, Nemoto K, Nakata E, Miyachi H, Takai Y, Yamada S.Intrinsic radiosensitivity by metallothionein expression has no great influence on clinical radiosensitivity in esophageal carcinoma. Oncol Rep. 2004 Dec;12(6):1195-9.
• Nomiya T, Nemoto K, Wada H, Takai Y, Yamada S. Advantage of accelerated fractionation regimens in definitive radiotherapy for stage II glottic carcinoma. Ann Otol Rhinol Laryngol. 115(10):727-732, 2006.
• Nomiya T, Nemoto K, Miyachi H, Fujimoto K, Takeda K, Ogawa Y, Takai Y, Yamada S.　Relationships between radiosensitivity and microvascular density in esophageal carcinoma: significance of hypoxic fraction.　Int J Radiat Oncol Biol Phys. 2004 Feb 1;58(2):589-96.
• Nomiya T, Nemoto K, Miyachi H, Fujimoto K, Takahashi C, Takeda K, Matushita H, Ogawa Y, Takai Y, Yamada S. Significance of plasminogen-activation system in the formation of macroscopic types and invasion in esophageal carcinoma.　Anticancer Res. 2002 Sep-Oct; 22(5):2913-6.

No content available to display!!!

No content available to display!!!